PATENT CLAIM ANALYSIS

Application Number: 15755140
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "252160"]

Abstract:
The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha-isoform specific P13K inhibitor, (b) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, and (c) an antimetabolite antineoplastic agent; combined preparations and pharmaceutical compositions thereof; the uses of such a combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

Claim (Index 10):
The method according to  claim 7 , wherein the cancer is colon cancer, rectal cancer, colorectal cancer, breast cancer, stomach cancer, or pancreatic cancer.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 88.0
- Lexical Diversity: 1.58824
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15755122', '13055541', '12600019', '14651297', '13425817']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7607497478623485
- 35 USC 102 Novelty (BERT): 0.5236127286282056
- Combined Prediction Score: 0.7370360459389342
- Mean Citation Score: 283.932718
- Max Citation Score: 308.38382
- Similarity Product: 233.6187916923678

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test